Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
15
0
0
8
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
26.7%
4 terminated out of 15 trials
66.7%
-19.8% vs benchmark
7%
1 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine
COVID-19 and Anti-CD14 Treatment Trial
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (COVID-19) Status (Positive or Negative) During Hospitalization
Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
The Effectiveness of Phytotherapy in SARS-COV2(COVID-19)
Study to Assess the Efficacy and Safety of Favipiravir-HU
A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection
Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)
Convalescent Plasma in the Treatment of COVID 19